Acta Neurologica Scandinavica最新文献

{"title":"Safety and Efficacy of Intravenous Alteplase for Acute Ischaemic Stroke in Patients With Prestroke Symptomaticity: An Analysis of the Virtual International Stroke Trials Archive","authors":"Jenny Simon,&nbsp;Michał Karliński,&nbsp;Maciej Niewada,&nbsp;VISTA-Acute Collaboration","doi":"10.1155/ane/1355429","DOIUrl":"https://doi.org/10.1155/ane/1355429","url":null,"abstract":"<p><b>Background:</b> Randomised controlled trials (RCTs) for intravenous thrombolysis (IVT) in acute ischaemic stroke (AIS) historically excluded patients with pre-existing disability. This tradition echoes in clinical practice, despite evidence suggesting IVT improves chances of returning to prestroke functional status. We investigated the role of pre-existing symptomaticity by comparing IVT-treated versus IVT-withheld Modified Rankin Scale (mRS) 1 patients and mRS 0 versus mRS 1 IVT-treated patients.</p><p><b>Methods:</b> The Virtual International Stroke Trials Archive (VISTA) has collated data from 38 AIS RCTs. Patients enrolled in trials whose investigative treatments reported no significant effect on outcomes or that were placebo-treated were eligible, yielding 3175 individual patient records. 2454 patients had prestroke mRS 0, and 721 had prestroke mRS 1. The negligible number of patients with prestroke mRS ≥ 2 prompted focus on prestroke mRS 1 patients. Propensity score and logistic regression were used to compare intracranial haemorrhage (ICH), neurological improvement, mortality, and functional outcome within 90 days.</p><p><b>Results:</b> Of IVT-treated patients, mRS 1 subjects were female in higher proportion and had a more frequent history of stroke than mRS 0 subjects. Of mRS 1 patients, IVT-withheld subjects were older and had a more frequent history of stroke than IVT-treated subjects. No significant differences were found for National Institutes of Health Stroke Scale (NIHSS) severity and other baseline parameters. IVT-treated patients achieved significant neurological improvement more frequently than IVT-withheld patients (40.5% vs. 27.9%, <i>p</i> = 0.028; adjusted odds ratio (aOR) 1.53, 95% confidence interval (95% CI): 1.18–1.88), with no significant differences in mortality and favourable functional outcome. ICH was numerically higher among IVT-treated patients; however, this did not persist after matching and regression adjustment. Comparing IVT-treated mRS 0 and mRS 1 patients revealed no significant differences.</p><p><b>Conclusion:</b> Our post hoc analysis of randomised data provides reassurance that IVT is safe and offers significant clinical benefit for AIS patients with pre-existing symptomaticity, as measured by the NIHSS. The lack of marked improvement on the mRS substantiates that the NIHSS is a key secondary outcome measure to capture recovery trajectories in studies concerned with reperfusion therapies.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2025 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/1355429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143117448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of CT and MR Venography in Acute Cerebral Venous Thrombosis","authors":"Silja Räty,&nbsp;Sini Hiltunen,&nbsp;Georgios Georgiopoulos,&nbsp;Anastasia Adamou,&nbsp;Erold Ajdini,&nbsp;Pekka Virtanen,&nbsp;Antti Korvenoja,&nbsp;George Ntaios,&nbsp;Jukka Putaala,&nbsp;Daniel Strbian","doi":"10.1155/ane/5712133","DOIUrl":"https://doi.org/10.1155/ane/5712133","url":null,"abstract":"<p><b>Background:</b> Cerebral venous thrombosis (CVT) is a rare cause of stroke with variable clinical presentation and challenging diagnosis. Computed tomography venography (CT-V) or magnetic resonance venography (MR-V) are recommended for detecting CVT, but their diagnostic performance is unclear. This systematic review examines the accuracy of CT-V and MR-V in diagnosing CVT.</p><p><b>Methods:</b> We performed a systematic literature search up to 02 July 2023 to retrieve original articles studying the diagnostic accuracy of CT-V or MR-V in patients with suspected CVT. Studies with a reference standard comprising at least one other imaging method alone or in addition to clinical data were included. The quality of studies was assessed with the QUADAS-2 tool.</p><p><b>Results:</b> We found eight studies (478 subjects) published between 1995 and 2022 that compared one or more diagnostic methods to a reference: CT-V (four studies, <i>n</i> = 95) and/or MR-V (three studies, <i>n</i> = 83) versus clinical and radiological consensus, CT-V versus MR-V (two studies, <i>n</i> = 292), or MR-V versus digital subtraction angiography (DSA) (one study, <i>n</i> = 52). They reported excellent diagnostic accuracy for both CT-V (sensitivity 100%, specificity 94%–100%) and MR-V (sensitivity 90%–100%, specificity 71%–100%) compared to clinical and radiological consensus, for CT-V compared to MR-V (sensitivity 96%–100%, specificity 99%–100%), and for MR-V compared to DSA (sensitivity 100%, specificity 71%). The heterogeneity of the studies allowed only an exploratory meta-analysis. The risk of bias in the use of the reference standard was high.</p><p><b>Conclusions:</b> Our systematic review found a high accuracy of CT-V and MR-V for detecting CVT, suggesting that CT-V is a feasible option for centers with limited access to MR-V. However, the small sample sizes and variable reference methods impair conclusions drawn from the current literature.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2025 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5712133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143112695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom","authors":"Samuel Díaz-Insa,&nbsp;Sonia Santos-Lasaosa,&nbsp;Maurice T. Driessen,&nbsp;Joshua M. Cohen,&nbsp;Lulu Lee,&nbsp;Peter J. Goadsby","doi":"10.1155/ane/4714514","DOIUrl":"https://doi.org/10.1155/ane/4714514","url":null,"abstract":"<p><b>Objectives:</b> Migraine affects more than 80 million people in Western Europe. The present study evaluated disability and health-related quality of life (HRQoL) among patients with episodic migraine (EM) and chronic migraine (CM) who had failed multiple preventive treatments.</p><p><b>Materials and Methods:</b> This study was an analysis of cross-sectional, web-based survey data from adult patients with migraine (EM and CM) from the United Kingdom, France, and Spain who had self-reported failure of two or more preventive treatments. Patient characteristics and patient-reported HRQoL, migraine-related disability, healthcare resource use (HCRU), and burden of migraine were evaluated by classification (CM and EM) and country (EM only).</p><p><b>Results:</b> In this sample of 316 patients (United Kingdom, <i>n</i> = 106; Spain, <i>n</i> = 105; France, <i>n</i> = 105), 76 (24.1%) patients had CM, the mean (standard deviation [SD]) age was 39.5 (12.3) years, and 164 (51.9%) patients were female. Those patients with CM reported greater migraine-related disability based on Migraine Disability Assessment (MIDAS) scores versus those with EM (mean [SD]: 43.8 [44.7] vs. 23.2 [28.3]), as well as greater pain-related impact on daily activities and higher HCRU. Among patients with EM, MIDAS scores indicated disability was severe in Spain (mean [SD]: 31.6 [31.1]) and France (24.3 [31.1]) and moderate in the United Kingdom (13.8 [17.9]), while HRQoL was similar across countries. Regarding the burden of EM, higher levels of pain and symptom-related interference with many aspects of life, including occupational functioning, were reported in the United Kingdom and Spain versus France.</p><p><b>Conclusions:</b> Migraine is associated with substantial disability and decreased HRQoL among patients who have failed previous preventive therapies. Although migraine burden varied by country, the results suggest high unmet needs in all countries. Appropriate treatment could reduce migraine-related burden and HCRU among patients with difficult-to-treat migraine.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/4714514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142860770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Morphometry Differences Between Children With Autism Spectrum Disorder and Healthy Individuals in a Middle Eastern Population: A Cross-Sectional Retrospective Study","authors":"Naif A. Majrashi,&nbsp;Rafat Mohtasib,&nbsp;Ahmed Masawi,&nbsp;Abdullah Almujally,&nbsp;Ali S. Alyami,&nbsp;Ali Hendi,&nbsp;Wael Ageeli,&nbsp;Yahia Madkhali,&nbsp;Bandar Alwadani,&nbsp;Turkey Refaee","doi":"10.1155/2024/8797606","DOIUrl":"https://doi.org/10.1155/2024/8797606","url":null,"abstract":"<p>This study is aimed at investigating brain morphometry differences between children with ASD and healthy controls (HCs) in Saudi Arabia and exploring the association between IQ levels and brain volumes within the ASD group. Participants (<i>N</i> = 29, 31.1% females and 68.9% males) ranging in age from 6 to 17 years were scanned by MRI at the King Faisal Specialist Hospital and Research Center (KFSHRC). Brain volumes were analyzed while correcting for age, sex, and total intracranial volume (TICV). The analysis revealed that individuals with ASD exhibited larger volumes compared to HCs in the left caudate (<i>p</i> &lt; 0.001), right caudate (<i>p</i> &lt; 0.001), total caudate (<i>p</i> &lt; 0.001), and total hippocampus (<i>p</i> = 0.014). These findings provide evidence for anatomical brain abnormalities in individuals with ASD and highlight the heterogeneity of these differences across brain regions. Furthermore, the analysis revealed that higher IQ levels were negatively associated with the volumes of the left thalamus, left pallidum, left accumbens area, right thalamus, right hippocampus, and total thalamus but positively correlated with the third lateral ventricle volume in HCs, <i>p</i> &lt; 0.05. These results suggest a meaningful relationship between cognitive abilities, as measured by IQ, and variations in brain volumes in HCs. The study significantly contributes to the understanding of the neurobiology of ASD in a Middle Eastern population and emphasizes the importance of considering cognitive functioning in relation to brain morphology in ASD research and clinical practice.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8797606","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Titin Antibody Is Linked to Increased Hospitalization Rates in Nonthymoma Myasthenia Gravis in Central China","authors":"Lulu Zhen,&nbsp;Xue Zhao,&nbsp;Jinru Wu,&nbsp;Yingna Zhang,&nbsp;Haodong Shang,&nbsp;Xinru Shen,&nbsp;Shufan Chen,&nbsp;Xiaoyan Zhu,&nbsp;Hanbin Liu,&nbsp;Jing Zhang,&nbsp;Junhong Yang,&nbsp;Hua Fang,&nbsp;Yunke Zhang,&nbsp;Qingyong Zhang,&nbsp;Xinzheng Cui,&nbsp;Jie Lv,&nbsp;Feng Gao","doi":"10.1155/ane/6343332","DOIUrl":"https://doi.org/10.1155/ane/6343332","url":null,"abstract":"<p>Insufficient evidence exists to assess the effect of titin antibodies on nonthymoma myasthenia gravis (MG) treatment and prognosis. We analyzed whether titin antibody-positive patients with nonthymoma MG (non-TMG) have a higher frequency of hospitalization than those who are titin antibody-negative. We retrospectively analyzed patient data from January 2017 to July 2022 obtained from an institutional databank. We compared the clinical characteristics, treatment regimens, and MG-related annual hospitalization rate between titin antibody-positive (Titin+ group) and titin antibody-negative (Titin− group) patients with non-TMG. Multivariate logistic regression was employed to examine the factors associated with multiple hospital admissions (≥ 2). Finally, 170 patients with non-TMG were included, of whom 67 (39.4%) were Titin+ and 103 (60.6%) were Titin−. Compared with the Titin− group, the Titin+ group exhibited a notably higher annual hospitalization rate (<i>p</i> = 0.011). Multivariate logistic regression analysis revealed that titin antibody positivity was significantly associated with multiple hospitalizations. The optimal cutoff value for titin antibody levels related to multiple hospitalizations was 3.085. In patients with non-TMG, titin antibodies were associated with more frequent hospitalizations. For these patients, especially those with titers ≥ 3.085, close monitoring of clinical symptom changes may reduce relapse.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/6343332","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of Salivary Cortisol Levels With Depression, Anxiety, and Quality of Life in Male Relapsing-Remitting Multiple Sclerosis Patients: A Case-Control Study","authors":"Yousef Mokary,&nbsp;Saeed Vaheb,&nbsp;Mohammad Yazdan Panah,&nbsp;Alireza Afshari-Safavi,&nbsp;Elham Moases Ghaffary,&nbsp;Mahdi Barzegar,&nbsp;Ali Shirbacheh,&nbsp;Vahid Shaygannejad,&nbsp;Omid Mirmosayyeb","doi":"10.1155/2024/8728071","DOIUrl":"https://doi.org/10.1155/2024/8728071","url":null,"abstract":"<p><b>Background:</b> Dysfunctions of the hypothalamic-pituitary-adrenal (HPA) axis can trigger multiple sclerosis (MS) symptoms. Mood disorders comorbid with MS are implicated in the HPA axis activation in most people with MS (pwMS). This study purposed to examine salivary cortisol (SC) levels and their association with mood disorders in pwMS.</p><p><b>Methods:</b> Forty-three men as pwMS and sixteen men as healthy controls (HC) were included in this study. pwMS and HC completed the Beck Depression Inventory (BDI), 36-Item Short Form Survey (SF-36), Fatigue Severity Scale (FSS), Depression Anxiety and Stress Scale, and Hospital Anxiety and Depression Scale questionnaires. SC levels were also measured in pwMS and HC. A linear regression model was used to analyze the relationship between the Expanded Disability Status Scale (EDSS) and mood disorders and SC levels. Pearson’s or Spearman’s tests examined the correlation between SC levels and mood disorders.</p><p><b>Results:</b> The SC level, anxiety, depression, fatigue, and stress were significantly higher in pwMS than in HC (<i>p</i> &lt; 0.05). pwMS also showed significant correlations between SC levels and role physical (<i>r</i> = 0.3, <i>p</i> &lt; 0.05) and emotional (<i>r</i> = 0.34, <i>p</i> &lt; 0.05) in SF-36. Among SF-36 domains, only general health (<i>β</i> = −0.72, <i>p</i> &lt; 0.05) and physical functioning (<i>β</i> = −1.61, <i>p</i> &lt; 0.05) were negatively associated with disease duration. No correlation was found between SC levels and anxiety, depression, and fatigue (<i>p</i> &gt; 0.05).</p><p><b>Conclusions:</b> The pwMS showed mild to moderate depression, anxiety, and fatigue. Only general health and physical functioning as aspects of quality of life were related to disease duration, while SC levels, mood disorders, and other quality-of-life domains were not associated with clinical characteristics. Also, this study failed to find a significant role for SC as a valuable marker in approaching mood disorders in pwMS.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/8728071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142664746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eculizumab Versus Rituximab for Refractory Antiacetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: A Single-Center Experience","authors":"Hacer Durmus,&nbsp;Arman Çakar,&nbsp;Yesim Gülşen Parman","doi":"10.1155/2024/9924598","DOIUrl":"https://doi.org/10.1155/2024/9924598","url":null,"abstract":"<p><b>Background:</b> Rituximab (RTX) and eculizumab (ECU) are treatment options for refractory myasthenia gravis (MG), but comparative clinical data derived from real-world experience are limited. Here, we describe the baseline characteristics, treatment, and safety outcomes of patients with antiacetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) treated with ECU and/or RTX in our clinic.</p><p><b>Methods:</b> Patients with refractory AChR+ gMG who received ECU or/and RTX treatment for more than 1 year at the Department of Neurology, Istanbul Faculty of Medicine were included in this observational study. After obtaining written patient consent, data were collected retrospectively from medical records.</p><p><b>Results:</b> Twelve patients treated with ECU and 25 patients treated with RTX were included in the analysis. Groups were comparable with regard to demographic and clinical characteristics, including age at onset of MG, disease duration, and history of thymoma. ECU was associated with significantly better outcomes compared with RTX, as measured by decreases in the mean MG activities of daily living score at 1 (<i>p</i> = 0.024), 3 (<i>p</i> &lt; 0.001), 6 (<i>p</i> &lt; 0.001), and 12 (<i>p</i> &lt; 0.001) months of treatment; steroid-sparing effect after 1 year of treatment (decrease in mean [standard deviation] daily prednisolone dose of −21.8 mg [13.5] vs. −6.6 mg [9.4] with RTX; <i>p</i> &lt; 0.001); and need for rescue treatment and number of myasthenic crisis episodes during treatment (<i>p</i> &lt; 0.001). No new safety signals were observed with either treatment.</p><p><b>Conclusion:</b> Our data provide real-world evidence supporting ECU over RTX to treat patients with refractory AChR+ gMG.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9924598","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142664828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Depression on Cognitive Function and Phenoconversion to Neurodegenerative Diseases in Patients With Isolated REM Sleep Behavior Disorder","authors":"Seock Hyeon Moon,&nbsp;Jung Kyung Hong,&nbsp;Minji Lee,&nbsp;Hak Hyeon Kim,&nbsp;In-Young Yoon","doi":"10.1155/ane/9980063","DOIUrl":"https://doi.org/10.1155/ane/9980063","url":null,"abstract":"<p><b>Background:</b> This study was aimed at analyzing cognitive function and quantitative electroencephalogram (qEEG) in patients with isolated REM sleep behavior disorder (iRBD) based on the presence of depression and at evaluating the impact of depression on phenoconversion to neurodegenerative diseases.</p><p><b>Methods:</b> Individuals diagnosed with iRBD via polysomnography were included. Based on the presence of depression, patients were categorized into two groups. Neuropsychological tests and qEEG were conducted following the diagnosis of iRBD, and outcomes were compared between the two groups. Patients were regularly followed to monitor their phenoconversion status. Cox regression analysis was performed to assess the hazard ratio associated with depression.</p><p><b>Results:</b> Ninety iRBD patients (70% males) were included, with a median age of 66.3 years. Depression was identified in 26 (28.9%) of these patients. The depressed group showed significantly poorer performance only in color reading subtest of Stroop (<i>p</i> = 0.029) compared to the nondepressed group, showing reduced processing speed. In qEEG, relative gamma power (<i>p</i> = 0.034) and high gamma power (<i>p</i> = 0.020) in the parietal region were significantly higher in the depressed group than in the nondepressed group. Depression was associated with a hazard ratio of 3.32 for the risk of phenoconversion to neurodegenerative diseases in iRBD patients (<i>p</i> = 0.011).</p><p><b>Conclusion:</b> Depressive symptoms in iRBD patients should be closely monitored as they could aggravate cognitive dysfunction and increase the risk of phenoconversion to neurodegenerative diseases.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/9980063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142664827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capacity Limitations and Work Ability in Patients With Neurological Conditions With and Without Work Phobic Anxiety","authors":"Anne Henning,&nbsp;Beate Muschalla","doi":"10.1155/2024/6674418","DOIUrl":"https://doi.org/10.1155/2024/6674418","url":null,"abstract":"<p><b>Objective:</b> Work phobic anxiety can occur as an additional problem in any somatic illness and is often associated with work capacity limitations and sick leave. This study investigates work-related capacity limitations in patients with and without work phobic anxiety who are undergoing neurological rehabilitation. It was conducted in the rehabilitation facility Brandenburgklinik Berlin-Brandenburg in Germany.</p><p><b>Methods:</b> Work phobic anxiety was assessed with the Workplace Phobia Scale (WPS). The response rate was 69.51%. Capacity limitations (Mini-ICF-APP) were compared between 19 patients with neurological conditions and work phobic anxiety and 209 patients with neurological conditions without work phobic anxiety. Work participation restrictions were examined and compared using the self- and observer rated Index for Measuring Participation (IMET, IMEP-O). The work ability assessments regarding the patients’ last occupation as well as the general labor market were conducted by the treating physicians as part of their medical reports and compared between the subgroups. The work ability was rated as less than 3 h, 3 to less than 6 h, or 6 h or more a day for more than 6 months, with the latter being an indication for prognostic work ability and potential reintegration into the labor market. This is a common classification in sociomedical assessments in Germany.</p><p><b>Results:</b> Independent <i>t</i>-tests showed that patients with work phobic anxiety were significantly more limited in their planning and structuring of tasks (<i>t</i>[20.104] = 2.310, <i>p</i> = 0.032, <i>d</i> = 0.68), flexibility (<i>t</i>[217] = 3.586, <i>p</i> &lt; 0.001, <i>d</i> = 0.86), assertiveness (<i>t</i>[19.613] = 2.151, <i>p</i> = 0.044, <i>d</i> = 0.70), group integration (<i>t</i>[19.534] = 2.274, <i>p</i> = 0.034, <i>d</i> = 0.76), and mobility capacities (<i>t</i>[16.616] = 2.198, <i>p</i> = 0.042, <i>d</i> = 0.76) and significantly more restricted in participating in work compared to patients without work phobic anxiety (IMEP-O: <i>t</i>[23.549] = 2.298, <i>p</i> = 0.031, <i>d</i> = 0.40; IMET: <i>t</i>[27.191] = 4.581, <i>p</i> &lt; 0.001, <i>d</i> = 0.78). Chi-squared tests revealed no significant differences in the physicians’ work ability assessments between patients with and without work phobic anxiety.</p><p><b>Conclusions:</b> While work phobic anxiety seems to not be decisive concerning early retirement assessments, it is associated with greater capacity limitations and work participation restrictions. The results highlight the need for identifying work phobic anxiety and associated capacity limitations in clinical practice.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/6674418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142664567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients","authors":"Raquel Gasque-Rubio,&nbsp;Laura Cubas-Nuñez,&nbsp;Jordi Tortosa-Carreres,&nbsp;Lorena Forés-Toribio,&nbsp;Jéssica Castillo-Villalba,&nbsp;Sara Carratalá-Boscá,&nbsp;Carmen Alcalá-Vicente,&nbsp;Carlos Quintanilla-Bordás,&nbsp;David Gorriz,&nbsp;Francisco Gascón-Gimenez,&nbsp;Guillermo Cervera-Ygual,&nbsp;José Andrés Dominguez-Morán,&nbsp;María Carcelén-Gadea,&nbsp;Begoña Laiz Marro,&nbsp;Bonaventura Casanova,&nbsp;Francisco Pérez-Miralles","doi":"10.1155/2024/1950913","DOIUrl":"https://doi.org/10.1155/2024/1950913","url":null,"abstract":"<p><b>Background</b>: The assessment of serum neurofilament light chain (sNfL) is increasingly significant in the field of neurology. In multiple sclerosis (MS), it proves valuable as a marker for monitoring disease activity and treatment response.</p><p><b>Objective</b>: To compare the Simoa and Lumipulse platforms for measuring sNfL and to establish age-specific reference ranges within a substantial cohort of individuals diagnosed with MS.</p><p><b>Methods:</b> Two hundred sixty-one sNfL measurements from a cohort of 229 MS patients were analyzed with Simoa and Lumipulse. Reference ranges for sNfL were established for three age groups (18–39 years, 40–59 years, and &gt; 60 years) selecting data from 166 patients with stable relapsing–remitting MS.</p><p><b>Results:</b> While sNfL levels correlated between assays, Lumipulse exhibited values higher than Simoa. Passing–Bablok’s analysis confirmed linearity between the two datasets, and the Bland–Altman comparison further supported the agreement between the methods. Analyzing reference ranges for sNfL across three age groups in stable RRMS patients revealed significant differences between the groups on each of the platforms. Although the values followed the same trend, each technology utilized distinct reference ranges.</p><p><b>Conclusion:</b> Simoa and Lumipulse platforms proved equally effective in monitoring patients with MS. The enhanced accessibility of the Lumipulse platform facilitates the expansion of research on sNfL as a biomarker for monitoring MS, thus offering promising opportunities for broader accessibility and advancement in this field.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2024 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/1950913","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}